Basic information Safety Related
(+/-)-2,5-DIMETHOXY-4-BROMO-AMPHETAMINE HYDROBROMIDE Structure

(+/-)-2,5-DIMETHOXY-4-BROMO-AMPHETAMINE HYDROBROMIDE

Chemical Properties

EWG's Food Scores 1
FDA UNII 1S6K9S6785

Safety

Symbol(GHS) GHS hazard pictograms
Signal wordDanger
Hazard statements H302-H310-H330
Precautionary statements P264-P270-P301+P312-P330-P501-P262-P264-P270-P280-P302+P350-P310-P322-P361-P363-P405-P501-P260-P271-P284-P304+P340-P310-P320-P403+P233-P405-P501
Hazard Codes  T+
Risk Statements  26/27/28
Safety Statements  28-36/37-45
RIDADR  UN 2811 6.1/PG 2
WGK Germany  3
RTECS  SH0300000
HazardClass  6.1(a)
PackingGroup  I
Toxicity A hallucinogenic (psychedelic) agent that is obtained by chemical synthesis. It may catalyze severe emotional problems or psychosis in predisposed individuals, and in large doses, produces peripheral arterial spasm which, if not treated, can lead to gangrene. DOB is a potent serotonin 5-HT2 agonist, and although the underlying mechanism of action for hallucinogens is not well understood, this may be related to its actions in the CNS. Symptoms include hyperreflexia, restlessness, perceptual alterations, and illusions, including changes in touch, taste, and odor, and the thinking process is substantially altered. At high doses, it causes hallucinations, loss of contact with reality, and pain and coldness in the extremities at toxic levels. Therapeutically, peripheral arterial spasm has been treated with intraarterial tolazoline hydrochloride. Its LD50 is in mice 80 mg/kg, i.v., in rats 8 mg/kg, i.p., in dogs 4 mg/kg. i.v., and in monkeys 2 mg/kg, i.v.

Preparation Products And Raw materials